Walk n #39; Roll for Children #39;s Specialized Hospital May 17, 2014
The 8th annual Walk n #39; Roll for Children #39;s Specialized Hospital will take place on May 17, 2014. This event has welcomed thousands of supporters each year to...

By: Children #39;s Specialized Hospital

Continue reading here:
Walk n' Roll for Children's Specialized Hospital May 17, 2014 - Video

Recommendation and review posted by sam

MySCI (MY SPINAL CORD INJURY): Delineate Grant Program 2013 CAPS ONLY Version
Delineate is a small arts program that seeks to enrich the creative initiatives of the Don #39;t DIS my ABILITY campaign run by Ageing, Disability and Home Care ...

By: Accessible Arts

Link:
MySCI (MY SPINAL CORD INJURY): Delineate Grant Program 2013 CAPS ONLY Version - Video

Recommendation and review posted by sam

Neural Prolotherapy Testimonial #3
VinciHealth.com:Neural Prolotherapy is a powerfully effective new development in the world of regenerative medicine. One of several kinds of regenerative inj...

By: VinciHealth

See the rest here:
Neural Prolotherapy Testimonial #3 - Video

Recommendation and review posted by sam

Prolotherapy Testimonial #1
VinciHealth.com;Prolotherapy Professional athletes, weekend warriors and the unfortunates who suffered as a result of accidents have turned to regenerative m...

By: VinciHealth

Link:
Prolotherapy Testimonial #1 - Video

Recommendation and review posted by sam

Bone marrow stem cells needed

By: RBCLife Malaysia

Here is the original post:
Bone marrow stem cells needed - Video

Recommendation and review posted by Bethany Smith

By Estel Grace Masangkay

CardioCell LLC announced that it has received FDA approval for its investigational new drug (IND) application for a U.S.-based Phase IIA clinical study evaluating its allogeneic stem-cell therapy for patients with chronic heart failure (CHF).

Dr. Sergey Sikora, CardioCells president and CEO, said, With the FDAs IND approval, CardioCell is pleased to proceed with a Phase 2a CHF clinical trial based on the safety data reported in previous clinical trials using our unique, hypoxically grown stem cells. At the studys conclusion we will understand if our therapy produces signs of improvement in a population of patients with dilated CHF, a condition largely unaddressed by current therapies. Dilated CHF is characterized by a viable but non-functioning myocardium in which cardiomyocytes are alive but are not contracting as they should. We hope that unique properties of our itMSCs will transition patients cardiomyocytes from viable to functioning, eventually improving or restoring heart function.

The company has developed an ischemic tolerant mesenchymal stem cells (itMSC) treatment for the type of dilated CHF that is not related to coronary artery disease. The treatment could potentially apply to about 35 percent of CHF patients. Only CardioCells CHF therapies feature itMSCs, exclusively licensed from CardioCells parent company Stemedica Cell Technologies Inc. The company said Stemedicas bone marrow-derived, allogeneic MSCs are different from other MSCs because they are grown under hypoxic conditions that closely resemble the environment in which they thrive on in the body.

Dr. Stephen Epstein, CardioCells Scientific Advisory Board Chair, said Although past trials have tested the efficacy of different stem cells in patients with DCM, CardioCells itMSCs, grown under chronic hypoxic conditions, are unique. As compared to stem cells grown under normoxic conditions, they express higher levels of factors that could exert beneficial effects on the mechanisms contributing to myocardial dysfunction and disease progression. This study, therefore, provides an exciting opportunity to test the potential of these itMSCs to attenuate or eliminate these mechanisms and, in so doing, improve patient outcomes.

The trial entitled A Phase 2a, Single-Blind, Placebo-Controlled, Crossover, Multi-Center, Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-Tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Heart Failure of Non-Ischemic Etiology, will be conducted at Emory University, Northwestern University, and the University of Pennsylvania in May this year.

Go here to read the rest:
FDA Approves CardioCell's Phase 2A Trial For CHF Stem Cell Therapy

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

4-Apr-2014

Contact: Lisa Merkl lkmerkl@uh.edu 713-743-8192 University of Houston

HOUSTON, April 4, 2014 A long-standing challenge in synthetic biology has been to create gene circuits that behave in predictable and robust ways. Mathematical modeling experts from the University of Houston (UH) collaborated with experimental biologists at Rice University to create a synthetic genetic clock that keeps accurate time across a range of temperatures. The findings were published in a recent issue of the Proceedings of the National Academy of Sciences.

"Synthetic gene circuits are often fragile, and environmental changes frequently alter their behavior," said Kreimir Josi, professor of mathematics in UH's College of Natural Sciences and Mathematics. "Our work focused on engineering a gene circuit not affected by temperature change."

Synthetic biology is a field in which naturally occurring biological systems are redesigned for various purposes, such as producing biofuel. The UH and Rice research targeted the bacterium E. coli.

"In E. coli and other bacteria, if you increase the temperature by about 10 degrees the rate of biochemical reactions will double and therefore genetic clocks will speed up," Josi said. "We wanted to create a synthetic gene clock that compensates for this increase in tempo and keeps accurate time, regardless of temperature."

The UH team, led by Josi and William Ott, an assistant professor of mathematics, collaborated with the lab of Matthew Bennett, assistant professor of biochemistry and cell biology at Rice. Josi, Bennett and Ott have been working together on various research projects for three years. The team also included UH postdoctoral fellow Chinmaya Gupta.

According to Bennett, the ability to keep cellular reactions accurately timed, regardless of temperature, may be valuable to synthetic biologists who wish to reprogram cellular regulatory mechanisms for biotechnology.

The work involved engineering a gene within the clock onto a plasmid, a little piece of DNA that is inserted into E. coli. A mutation in the gene had the effect of slowing down the clock as temperature increased.

Go here to see the original:
Math modeling integral to synthetic biology research

Recommendation and review posted by Bethany Smith

Tomato tomato genetic engineering rap
via YouTube Capture.

By: molly kramer

More:
Tomato tomato genetic engineering rap - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

4-Apr-2014

Contact: Allison Hydzik hydzikam@upmc.edu 412-559-2431 University of Pittsburgh Schools of the Health Sciences

SAN DIEGO, April 4, 2014 An examination of the genetic landscape of head and neck cancers indicates that while metastatic and primary tumor cells share similar mutations, recurrent disease is associated with gene alterations that could be exquisitely sensitive to an existing cancer drug. Researchers from the University of Pittsburgh Cancer Institute (UPCI) and Yale University School of Medicine will share their findings during a mini-symposium Sunday at the American Association for Cancer Research Annual Meeting 2014.

About 50 percent of patients diagnosed with head and neck squamous cell cancers already have disease that has spread, or metastasized, to the lymph nodes, explained Jennifer Grandis, M.D., distinguished professor and vice chair of research, Department of Otolaryngology, Pitt School of Medicine, and director of the Head and Neck Program at UPCI, partner with UPMC CancerCenter. About 20 to 30 percent of patients thought to be cured of the disease go on to develop recurrent cancer, which typically doesn't respond to standard treatments.

"We decided to compare the genetic signatures of tumor cells from primary tumors with those from disease that had spread and cancers that were thought cured but then came back in the hopes of getting some clues about how best to guide therapy in these different settings," Dr. Grandis said. "We found that recurrent cancers might have an Achilles' heel we can exploit to kill them."

The team conducted the first whole-exome genetic sequencing study on what Dr. Grandis called its "treasure trove" of frozen patient samples and found similar mutations both in primary tumors and in the lymph nodes to which their cancers had already spread. But there were different mutations in tumors that had recurred after a period of remission that were not found in their original cancers.

"The recurrent tumors carried mutations in a gene area that encodes for DDR2 cell receptors," Dr. Grandis said. "Other studies have shown that DDR2 mutations can confer sensitivity to the cancer drug dasatinib, which could mean that drug has promise in the treatment of recurrent head and neck cancers."

The researchers suggest that further investigation of dasatinib treatment is warranted.

###

More:
Recurrent head and neck tumors have gene mutations that could be vulnerable to cancer drug

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

4-Apr-2014

Contact: Kathy Ridgely Beal, M.B.A. kbeal@acmg.net 301-238-4582 American College of Medical Genetics

Huma Q. Rana, MD of Harvard Medical School's Dana Farber Cancer Institute is the recipient of the 2014 Richard King Trainee Award. This award was instituted five years ago by the ACMG Foundation for Genetic and Genomic Medicine to encourage ABMG or genetic counseling trainees in their careers and to foster the publication of the highest quality research in ACMG's peer-reviewed journal, Genetics in Medicine (GIM). Each year the editorial board reviews all articles published in GIM by an ABMG or genetic counseling trainee who was either a first or corresponding author during that year. The manuscript felt to have the most merit is selected by the editorial board and a cash prize awarded at the 2014 ACMG Annual Clinical Genetics Meeting.

Dr. Rana was given the award for her manuscript titled, " Age-Specific Parkinson Disease Risk in GBA Mutation Carriers: Information for Genetic Counseling" which was published in the February 2013 issue of Genetics in Medicine. The corresponding author was Roy Alcalay, MD, MS of Columbia University.

The award is given by the ACMG Foundation and is named for Dr. Richard King in recognition of his instrumental role in creating Genetics in Medicine and serving as the first and founding Editor-in-Chief of the journal.

Eligible trainees include those in the following programs: Clinical Biochemical Genetics; Clinical Cytogenetics; Clinical Molecular Genetics Combined Internal Medicine/Genetics; Combined Pediatrics/Genetics; PhD Medical Genetics and Genetic Counseling.

###

The ACMG Foundation for Genetic and Genomic Medicine, a 501(c)(3) nonprofit organization, is a community of supporters and contributors who understand the importance of medical genetics and genomics and genetic counseling in healthcare. Established in 1992, the ACMG Foundation supports the American College of Medical Genetics and Genomics' mission to "translate genes into health" by raising funds to promote the profession of medical genetics and genomics to medical students, to fund the training of future medical geneticists, to support best-practices and tools for practicing physicians and laboratory directors, to promote awareness and understanding of our work in the general public, and much more.

See the original post here:
Huma Rana, M.D., receives 2014 Richard King Award for best publication, Genetics in Medicine

Recommendation and review posted by Bethany Smith

April 4, 2014

This puppy is a Nova Scotia Duck Tolling Retriever, the breed with the newly discovered genetic mutation for cleft palate. (Danika Bannasch/UC Davis)

UC Davis School of Veterinary Medicine researchers have identified the genetic mutation responsible for a form of cleft palate in the dog breed Nova Scotia Duck Tolling Retrievers.

They hope that the discovery, which provides the first dog model for the craniofacial defect, will lead to a better understanding of cleft palate in humans. Although cleft palate is one of the most common birth defects in children, affecting approximately one in 1,500 live human births in the United States, it is not completely understood.

The findings appear this week online in the journal PLOS Genetics and are available online at https://tinyurl.com/knr8wb3.

This discovery provides novel insight into the genetic cause of a form of cleft palate through the use of a less conventional animal model, said Professor Danika Bannasch, a veterinary geneticist who led the study. It also demonstrates that dogs have multiple genetic causes of cleft palate that we anticipate will aid in the identification of additional candidate genes relevant to human cleft palate.

Bannasch, who holds the Maxine Adler endowed chair in genetics, explains that common breeding practices have made the dog a unique animal model to help understand the genetic basis of naturally occurring birth defects.

By conducting a genome-wide study of these particular retrievers with a naturally occurring cleft palate, researchers identified a mutation responsible for the development of cleft palate in the breed. Dogs with this mutation also have a shortened lower jaw, similar to humans who have Pierre Robin Sequence. The disorder, a subset of cleft palate, affects one in 8,500 live human births and is characterized by a cleft palate, shortened lower jaw and displacement of the tongue base.

Cleft palate condition occurs when there is a failure in the formation of the secondary palate, which makes up all of the soft palate and the majority of the hard palate. A disruption in the sequential steps of palate development causes a cleft palate and leads to the spectrum of cases that are observed. Children born with cleft palate may develop hearing loss and difficulties with speech and eating. They also may be at increased risk for neurological deficits.

Additional UC Davis researchers include: Zena T. Wolf, a graduate student in the Department of Population Health and Reproduction at the School of Veterinary Medicine, whose thesis topic is the study of craniofacial clefts in dogs; and Assistant Professor Boaz Arzi from the Department of Surgical and Radiological Sciences, School of Veterinary Medicine.

See the original post here:
Cleft palate discovery in dogs to aid in understanding human birth defect

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

4-Apr-2014

Contact: Allison Hydzik hydzikam@upmc.edu 412-559-2431 University of Pittsburgh Schools of the Health Sciences

SAN DIEGO, April 4, 2014 Genetic screening of cancer can help doctors customize treatments so that patients with melanoma have the best chance of beating it, according to the results of a clinical trial by researchers at the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter.

The trial, funded by the National Institutes of Health (NIH), will be presented Monday at the American Association for Cancer Research (AACR) Annual Meeting 2014. It showed that the cancer immune therapy drug ipilimumab appears most likely to prevent recurrence in patients whose cancer shows high expression of immune-related genes.

"We've reached a point in the treatment of melanoma and cancer in general where we're making major improvements in the outcomes of patients through personalized medicine," said lead investigator Ahmad Tarhini, M.D., Ph.D., associate professor of medicine and translational science in Pitt's Department of Medicine and Clinical and Translational Science Institute. "Anti-cancer therapy can be associated with significant side effects and economic costs. Therefore, we have a major interest in the development of tests that may allow us to predict which treatment regimen is most likely to help certain patients, while sparing others the unwanted side effects and cost of medications that are unlikely to work."

Before and after ipilimumab treatment, Dr. Tarhini and his colleagues obtained tumor biopsies used to run genetic tests on the tumors of 32 patients with advanced, stage 3 melanoma who were treated by UPMC. All patients were given standard-of-care surgery, which included complete surgical removal of an advanced tumor.

Patients with tumors that had higher levels of expression of a group of immune-related genes, either before or soon after treatment with ipilimumab, had 63 percent lower risk of cancer recurrence after surgery.

"By validating these findings in a large national trial that also will allow us to investigate other significant biomarker data, we'll seek to develop 'biomarker signatures' that doctors can use to customize melanoma treatment plans. The ultimate goals of therapy are to best treat the cancer in an individualized approach, while avoiding the unnecessary exposure of patients to severe side effects," said Dr. Tarhini.

###

Read the original here:
Genetic testing beneficial in melanoma treatment

Recommendation and review posted by Bethany Smith

Iron Man Genetics Ep 3 Attack of the B-Team
Today i mess around with some advanced genetics, with iron golem gene. Server: Come join me at tftgaming.com.

By: Critter86000

See original here:
Iron Man Genetics Ep 3 Attack of the B-Team - Video

Recommendation and review posted by Bethany Smith

European Population Genetics: Haplogroup E-M96 Part 5
I created this video with the YouTube Video Editor (http://www.youtube.com/editor)

By: phialen

See the original post:
European Population Genetics: Haplogroup E-M96 Part 5 - Video

Recommendation and review posted by Bethany Smith

2014 Masterpiece Genetics
Here is a sneek preview of the goats that Mastepiece Genetics is going to have available at the Breeders Select Prospect Goat Sale, Saturday April 5, 2014, a...

By: BreedersSelect

Read this article:
2014 Masterpiece Genetics - Video

Recommendation and review posted by Bethany Smith

Apothecary Genetics @ Spannabis 2014 Barcelona
Herbies Seeds Interview with Bret from Apothecary Genetics @ Spannabis 2014 in Barcelona Spain. Buy Apothecary Genetics Seeds http://www.herbiesheadshop.com/...

By: Herbies Seeds

Read more:
Apothecary Genetics @ Spannabis 2014 Barcelona - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

4-Apr-2014

Contact: Kathy Ridgely Beal, MBA kbeal@acmg.net 301-238-4582 American College of Medical Genetics

Paldeep S. Atwal, MD of Stanford University/Lucile Packard Children's Hospital and Jamie J. Barea, MD, of University of California, San Diego were honored as the 2014-2015 recipients of the Genzyme/ACMG Foundation Medical Genetics Training Award in Clinical Biochemical Genetics at the ACMG 2014 Annual Clinical Genetics Meeting in Nashville, TN.

The objective of the two Genzyme/ACMG Foundation Awards is to support a national training program to encourage the recruitment and training of clinicians in the field of clinical biochemical genetics and especially in the diagnosis, management and treatment of individuals with metabolic diseases. Two awardees are given the opportunity to participate in an in-depth clinical and research experience at a premier medical center with expertise and significant clinical volume in the area of biochemical genetics.

The Award grants $75,000 per year to each of two recipients' institution selected by the ACMG Foundation through a competitive process and will provide for the sponsorship of one year of the trainees' clinical genetics subspecialty in biochemical genetics following residency.

Dr. Atwal received his MD from the University Of Glasgow, Scotland; completed his internal medicine residency with The Royal College of Physicians of the United Kingdom at Glasgow Royal Infirmary, and is currently in the second year of residency in Medical Genetics at Stanford University/Lucile Packard Children's Hospital. His research during the award period will focus on perfecting a novel screening and diagnostic platform for diagnosing lysosomal storage diseases by newborn screening and as a clinical screening tool. He will continue his training as part of the Medical Biochemical Genetics Fellowship Program at Baylor College of Medicine.

"I am humbled to be granted the Genzyme/ACMG Foundation award. I am confident the Medical Biochemical Genetics Fellowship will provide a platform for me to provide the best clinical care possible for patients with inborn errors of metabolism including mitochondrial disorders whilst concurrently conducting translational research."

The second award recipient, Dr. Barea, is currently in his second year of residency in Medical Genetics at University of California- San Diego. He said, "I am honored and excited to be one of the recipients of the Genzyme/ACMG Foundation Award. This award will give me a great opportunity as a Biochemical Genetics fellow at UCSD to gain more knowledge and experience through clinical work and research. This experience will allow me to provide the best possible care for all of my future patients." Dr. Barea completed his MD at Tufts University School of Medicine in Boston, MA and a Pediatrics Residency at University of California, San Diego. His research during the Award period will involve a metabolomic study searching for biomarkers in Gaucher disease and Pompe disease.

"The Genzyme/ACMG Foundation Clinical Genetics Award in Clinical Biochemical Genetics is critical to the development of the genetics workforce. Biochemical genetics is undergoing particularly rapid change, as new insights into disease mechanisms are leading to new methods of treatment," said Bruce R. Korf, MD, PhD, FACMG, president of the ACMG Foundation.

Continue reading here:
2014-2015 Genzyme/ACMG Foundation Medical Genetics Training Award announced

Recommendation and review posted by Bethany Smith

SpinChat - Living with Spinal Cord Injury
Hear five young people share their experiences of acquiring and living with a spinal cord injury. SpinChat is a Victorian school-based program that raises awareness of spinal cord injury and...

By: Independence Australia

See the article here:
SpinChat - Living with Spinal Cord Injury - Video

Recommendation and review posted by sam

MiMedx Group

By: Alliance for Regenerative Medicine

Original post:
MiMedx Group - Video

Recommendation and review posted by sam

Sangamo BioSciences

By: Alliance for Regenerative Medicine

Original post:
Sangamo BioSciences - Video

Recommendation and review posted by sam

Promethera Biosciences

By: Alliance for Regenerative Medicine

Read more here:
Promethera Biosciences - Video

Recommendation and review posted by sam

TiGenix

By: Alliance for Regenerative Medicine

View post:
TiGenix - Video

Recommendation and review posted by sam

Prima Biomed

By: Alliance for Regenerative Medicine

More here:
Prima Biomed - Video

Recommendation and review posted by sam

Regen Med Investor Day 2014 | Program Introduction
Speaker: Geoff MacKay, Chair, Alliance for Regenerative Medicine (ARM); President CEO, Organogenesis Inc.

By: Alliance for Regenerative Medicine

Originally posted here:
Regen Med Investor Day 2014 | Program Introduction - Video

Recommendation and review posted by sam

Biomatrica

By: Alliance for Regenerative Medicine

Original post:
Biomatrica - Video

Recommendation and review posted by sam